Skip to content

Annexon ANNX Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
Omeros logo
OmerosOMER
Vor Biopharma logo
Vor BiopharmaVOR
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX

Segments

By geography

See full
Brisbane California$14.8M-9.2%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's operating lease right-of-use assets in other assets?
Annexon (ANNX) reported operating lease right-of-use assets in other assets of $14.77M in Q1 2026.
How has Annexon's operating lease right-of-use assets in other assets changed year-over-year?
Annexon's operating lease right-of-use assets in other assets decreased by 9.7% year-over-year, from $16.35M to $14.77M.
What is the long-term trend for Annexon's operating lease right-of-use assets in other assets?
Over 4 years (2021 to 2025), Annexon's operating lease right-of-use assets in other assets has grown at a -7.0% compound annual growth rate (CAGR), from $20.33M to $15.19M.